What is Fortress Biotech Inc's earnings per share (EPS)?

Fortress Biotech Inc (FBIOP) reported diluted earnings per share of -$0.07 for fiscal year 2025. This represents a 97.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Fortress Biotech Inc (FBIOP) Financials

FBIOP

Trailing 12 months to June 30, 2026

Revenue $68.5M +15.5% YoY

Net Income $142.0M +171.7% YoY

EPS (Diluted) $2.64 +351.4% YoY

Operating Cash Flow $125.9M +257.2% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the FBIOP SEC filings page.

Fortress Biotech Inc (FBIOP) reported $68.5M in revenue over the twelve months to Jun 30, 2026, up 15.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI FBIOP FY2025 2026-08-29

Reported profits are positive, but persistent operating cash outflows and financing inflows remain central to the business model.

The gap between positive net income and operating cash flow of -$65.8M in FY2025 indicates that reported earnings are not yet converting into cash from operations. That mismatch persisted from FY2023, when net income was $31M alongside operating cash flow of -$128.2M, making cash generation more informative than the bottom line alone.

Operating losses narrowed from -$142.3M in FY2023 to -$70.2M in FY2025 even as revenue remained below FY2023, while R&D fell from $106.1M to $11.9M. This combination points to expense restructuring or reduced development spending as a major driver of improved operating results, rather than scale alone.

The balance sheet became less debt-heavy: debt-to-equity declined from 2.5x in FY2024 to 1.1x in FY2025, while the current ratio rose from 126.6% to 248.9%. Financing inflows of $77.4M helped accompany that shift, so the stronger liquidity profile reflects both internal balance-sheet changes and external funding.

Financial Health Signals

Financial Health Score 28/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Fortress Biotech Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Fortress Biotech Inc's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 22/100.

Growth

Fortress Biotech Inc's revenue grew 9.7% year-over-year to $63.3M, a solid pace of expansion. This earns a growth score of 7/100.

Leverage

Fortress Biotech Inc has a moderate D/E ratio of 1.09. This balance of debt and equity financing earns a leverage score of 45/100.

Liquidity

With a current ratio of 2.49, Fortress Biotech Inc holds $2.49 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 70/100.

Cash Flow

Returns

Fortress Biotech Inc generates a 74.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 20/100. This is down from 92.4% the prior year.

Piotroski F-Score Neutral

5/9

Fortress Biotech Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

$1.78used

For every $1 of reported earnings, Fortress Biotech Inc used $1.78 of operating cash (-$65.8M OCF vs $37.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Interest Coverage At Risk

N/A

Fortress Biotech Inc reported an operating loss of $70.2M against $10.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$18.7M

YoY+14.0%

QoQ+16.7%

5Y CAGR+1.0%

10Y CAGR+23.7%

Fortress Biotech Inc generated $18.7M in revenue in Q2 2026. This represents an increase of 14.0% from the same quarter a year earlier. Against the prior quarter it is up 16.7%.

EBITDA

-$8.9M

YoY+74.7%

QoQ-37.1%

Fortress Biotech Inc's EBITDA was -$8.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 74.7% from the same quarter a year earlier. Against the prior quarter it is down 37.1%.

Net Income

-$468K

YoY-103.0%

QoQ-100.4%

Fortress Biotech Inc reported -$468K in net income in Q2 2026. This represents a decrease of 103.0% from the same quarter a year earlier. Against the prior quarter it is down 100.4%.

EPS (Diluted)

-$0.08

Fortress Biotech Inc earned -$0.08 per diluted share (EPS) in Q2 2026.

Cash & Balance Sheet

Cash & Debt

$196.6M

YoY+164.3%

QoQ-23.2%

5Y CAGR-6.5%

10Y CAGR+10.7%

Fortress Biotech Inc held $196.6M in cash against $35.0M in long-term debt as of Q2 2026.

Shares Outstanding

33M

5Y CAGR-19.3%

10Y CAGR-3.7%

Fortress Biotech Inc had 33M shares outstanding in Q2 2026.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

67.2%

YoY-2.7pp

QoQ+5.9pp

5Y CAGR+9.1pp

Fortress Biotech Inc's gross margin was 67.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 2.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.9 percentage points.

Operating Margin

-53.5%

QoQ-5.2pp

Fortress Biotech Inc's operating margin was -53.5% in Q2 2026, reflecting core business profitability. Against the prior quarter it is down 5.2 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

-2.5%

YoY-96.9pp

5Y CAGR+17.3pp

Fortress Biotech Inc's net profit margin was -2.5% in Q2 2026, showing the share of revenue converted to profit. This is down 96.9 percentage points from the same quarter a year earlier.

Return on Equity

-0.3%

YoY-35.6pp

QoQ-68.3pp

5Y CAGR+3.0pp

10Y CAGR+35.0pp

Fortress Biotech Inc's ROE was -0.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 35.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 68.3 percentage points.

Capital Allocation

R&D Spending

$805K

YoY-90.1%

QoQ+49.1%

5Y CAGR-52.7%

Fortress Biotech Inc invested $805K in research and development in Q2 2026. This represents a decrease of 90.1% from the same quarter a year earlier. Against the prior quarter it is up 49.1%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

FBIOP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FBIOP quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$68.5M	$63.3M+9.7%	$57.7M-31.8%	$84.5M+11.6%	$75.7M+10.1%	$68.8M+50.9%	$45.6M+24.5%	$36.6M+36.3%	$26.9M+55.9%	$17.2M+4.6%	$16.5M+1809.6%	$863K	$0	$0	N/A	N/A
Cost of Revenue	$23.6M	$20.9M+0.2%	$20.9M-8.8%	$22.9M-25.6%	$30.8M-4.1%	$32.1M+119.8%	$14.6M+38.6%	$10.5M+72.0%	$6.1M+67.4%	$3.7M+363.0%	$790K	$0	N/A	N/A	N/A	N/A
Gross Profit	$44.9M	$42.3M+15.1%	$36.8M-40.3%	$61.6M+37.0%	$45.0M+22.5%	$36.7M+18.4%	$31.0M+18.8%	$26.1M+25.7%	$20.8M+52.8%	$13.6M-13.4%	$15.7M+1718.1%	$863K	N/A	N/A	N/A	N/A
R&D Expenses	$1.2M	$11.9M-79.0%	$56.6M-46.6%	$106.1M-21.4%	$134.9M+4.7%	$128.9M+101.0%	$64.1M-21.2%	$81.3M-6.9%	$87.4M+80.8%	$48.3M+37.5%	$35.1M+17.9%	$29.8M+191.1%	$10.2M-60.1%	$25.7M+47.0%	$17.5M+103.5%	$8.6M
SG&A Expenses	$68.7M	$96.4M+9.9%	$87.7M-3.6%	$91.0M-20.0%	$113.7M+30.9%	$86.8M+42.0%	$61.2M+10.0%	$55.6M+4.2%	$53.4M+4.9%	$50.9M+80.3%	$28.2M+50.7%	$18.7M+79.9%	$10.4M+3.1%	$10.1M+16.5%	$8.7M+50.6%	$5.8M
Operating Income	-$29.2M	-$70.2M+36.4%	-$110.4M+22.5%	-$142.3M+30.1%	-$203.6M-8.0%	-$188.5M-100.0%	-$94.3M+14.9%	-$110.8M+7.6%	-$120.0M-33.6%	-$89.8M-36.7%	-$65.7M-30.0%	-$50.5M-144.7%	-$20.7M+42.3%	-$35.8M-31.7%	-$27.2M+22.5%	-$35.0M
EBITDA	N/A	-$65.6M+38.1%	-$105.9M+22.3%	-$136.3M+30.5%	-$196.2M-5.5%	-$185.9M-105.3%	-$90.6M+15.9%	-$107.7M+9.2%	-$118.6M-33.8%	-$88.6M-36.8%	-$64.8M-28.2%	-$50.5M-144.8%	-$20.6M+42.3%	-$35.8M-31.6%	-$27.2M+22.4%	-$35.0M
Interest Expense	$9.6M	$10.1M-25.3%	$13.5M-11.7%	$15.3M+22.7%	$12.5M-18.5%	$15.3M-0.1%	$15.3M+29.3%	$11.8M+114493.8%	$10K-99.8%	$5.9M+58.8%	$3.7M+148.7%	$1.5M+10.9%	$1.3M-30.4%	$1.9M+187.0%	$670K+805.4%	$74K
Income Tax	$4.8M	-$620K-298.7%	$312K-40.1%	$521K+16.0%	$449K-5.1%	$473K-5.4%	$500K	$0	$0-100.0%	$1.5M	$0	$0	N/A	N/A	N/A	N/A
Net Income	$142.0M	$37.0M+76.2%	$21.0M-32.3%	$31.0M+135.8%	-$86.6M-33.8%	-$64.7M-39.1%	-$46.5M-16.4%	-$40.0M+52.5%	-$84.1M-25.8%	-$66.9M-21.4%	-$55.1M-13.8%	-$48.4M-137.6%	-$20.4M+45.1%	-$37.2M-34.6%	-$27.6M+24.1%	-$36.4M
EPS (Basic)	N/A	-$0.07+97.4%	-$2.69+68.2%	-$8.47+47.0%	-$15.97-1921.5%	-$0.79	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$2.64	-$0.07+97.4%	-$2.69	-$8.47	-$15.97	-$0.79	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	28M+34.2%	21M	8M	6M	82M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$18.7M+14.0%	$16.0M+22.1%	$16.1M+6.3%	$17.6M+20.5%	$16.4M+10.2%	$13.1M+0.8%	$15.1M-24.2%	$14.6M-57.9%
Cost of Revenue	$6.1M+24.4%	$6.2M+29.8%	$5.4M+16.3%	$5.8M+28.7%	$4.9M-13.8%	$4.8M-20.2%	$4.7M+108.1%	$4.5M-30.5%
Gross Profit	$12.6M+9.6%	$9.8M+17.6%	$10.6M+1.9%	$11.9M+16.9%	$11.5M+25.1%	$8.3M+18.8%	$10.4M-41.0%	$10.2M-64.1%
R&D Expenses	$805K-90.1%	$540K-86.3%	-$371K-96.2%	$208K-97.8%	$8.1M-35.9%	$3.9M-84.1%	$9.7M-31.3%	$9.4M-53.6%
SG&A Expenses	$20.8M-46.3%	$15.9M-38.1%	$14.6M-46.0%	$17.4M-20.8%	$38.8M+86.1%	$25.7M+43.0%	$27.0M+38.6%	$22.0M+1.2%
Operating Income	-$10.0M+72.6%	-$7.7M+65.3%	-$4.6M+80.7%	-$6.8M+69.2%	-$36.5M-31.3%	-$22.3M+39.0%	-$23.9M-22.0%	-$22.1M-60.6%
EBITDA	-$8.9M+74.7%	-$6.5M+69.1%	-$3.5M+84.7%	-$5.6M+73.3%	-$35.3M-32.9%	-$21.1M+40.3%	-$22.8M-22.4%	-$21.2M-68.9%
Interest Expense	$1.5M-41.4%	$3.4M+20.1%	$2.0M-21.3%	$2.7M-55.8%	$2.5M+18.7%	$2.8M+7.8%	$2.6M+25.9%	$6.2M+145.0%
Income Tax	$320K	$5.1M	-$646K-365.8%	$26K-62.3%	$0	$0	$243K-36.1%	$69K-51.1%
Net Income	-$468K-103.0%	$110.4M+1142.8%	$26.2M-56.4%	$5.8M+145.5%	$15.5M+241.5%	-$10.6M+31.3%	$60.2M-26.9%	-$12.9M-155.0%
EPS (Basic)	-$0.08-116.0%	$3.44+816.7%	-$0.23+11.5%	$0.13+117.1%	$0.50+168.5%	-$0.48+53.8%	-$0.26+50.9%	-$0.76+19.1%
EPS (Diluted)	-$0.08	$2.82	-$0.21+19.2%	$0.11	$0.45	-$0.48+53.8%	-$0.26	-$0.76
Diluted Shares (Avg)	32M	38M	N/A	33M	30M	26M+54.2%	N/A	20M

FBIOP Balance Sheet

FBIOP quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$185.5M+28.7%	$144.2M-13.9%	$167.5M-43.1%	$294.3M-25.8%	$396.5M+18.9%	$333.4M+47.3%	$226.4M+60.6%	$141.0M-42.7%	$245.9M+44.1%	$170.7M+43.9%	$118.6M+32.8%	$89.3M-11.2%	$100.6M+145.4%	$41.0M+75.4%	$23.4M
Current Assets	$123.8M+37.0%	$90.4M-22.8%	$117.0M-49.2%	$230.4M-33.5%	$346.5M+30.2%	$266.1M+70.3%	$156.3M+40.5%	$111.2M-39.3%	$183.2M+67.1%	$109.6M+9.7%	$99.9M+41.8%	$70.5M-29.6%	$100.0M+146.4%	$40.6M+73.7%	$23.4M
Cash & Equivalents	$79.4M+38.6%	$57.3M-29.2%	$80.9M-54.6%	$178.3M-41.7%	$305.7M+31.0%	$233.4M+70.5%	$136.9M+108.9%	$65.5M-31.0%	$95.0M-9.7%	$105.2M+7.1%	$98.2M+97.3%	$49.8M-50.0%	$99.5M+147.6%	$40.2M+73.6%	$23.2M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0-100.0%	$17.6M-51.1%	$36.0M	$0	$0-100.0%	$20.0M	$0	$0	$0
Inventory	$9.6M-33.3%	$14.4M+41.4%	$10.2M-27.9%	$14.2M+43.6%	$9.9M+602.4%	$1.4M+63.8%	$857K+26.4%	$678K+296.5%	$171K-15.8%	$203K	$0	N/A	N/A	N/A	N/A
Accounts Receivable	$29.8M+191.1%	$10.2M-32.8%	$15.2M-46.0%	$28.2M+22.0%	$23.1M-3.4%	$23.9M+76.7%	$13.5M+146.3%	$5.5M-29.1%	$7.8M+323.9%	$1.8M	$0	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0-100.0%	$17.6M+57.6%	$11.1M	$0-100.0%	$1.4M-1.7%	$1.4M-43.1%	$2.5M-40.3%	$4.2M	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$18.6M0.0%	$18.6M	$0	N/A	N/A	N/A	N/A
Total Liabilities	$123.4M-15.4%	$145.9M-12.1%	$165.9M-32.1%	$244.3M-15.1%	$287.8M+23.5%	$233.1M+16.4%	$200.2M+65.1%	$121.3M-37.3%	$193.4M+46.2%	$132.2M+114.1%	$61.8M+228.5%	$18.8M-2.6%	$19.3M+1.8%	$19.0M+346.8%	$4.2M
Current Liabilities	$49.7M-30.3%	$71.4M-15.9%	$84.9M-33.5%	$127.7M+26.4%	$101.0M+95.2%	$51.8M+13.5%	$45.6M-18.0%	$55.6M-22.2%	$71.4M+26.3%	$56.6M+434.7%	$10.6M+159.5%	$4.1M-63.6%	$11.2M+118.4%	$5.1M+46.9%	$3.5M
Non-Current Liabilities	$73.6M-1.1%	$74.5M-8.1%	$81.0M-30.5%	$116.6M-37.6%	$186.8M+3.0%	$181.3M+17.3%	$154.6M+135.5%	$65.6M-46.2%	$121.9M+61.1%	$75.7M+47.8%	$51.2M+247.6%	$14.7M+1267.2%	$1.1M-92.2%	$13.8M+1743.6%	$750K
Long-Term Debt	$54.5M-6.0%	$58.0M-4.8%	$60.9M-33.7%	$91.7M+113.6%	$42.9M-16.9%	$51.7M-39.0%	$84.7M+0.3%	$84.4M+25.0%	$67.5M+123.5%	$30.2M+25.9%	$24.0M+71.4%	$14.0M	N/A	N/A	N/A
Total Equity	$49.9M+119.3%	$22.7M+0.9%	$22.5M-46.0%	$41.7M-61.6%	$108.7M+8.3%	$100.3M+282.8%	$26.2M+1315.5%	$1.9M-96.5%	$52.6M+36.6%	$38.5M-32.3%	$56.8M-19.4%	$70.5M-13.2%	$81.3M+268.9%	$22.0M+15.2%	$19.1M
Retained Earnings	-$734.1M+0.9%	-$740.9M-6.6%	-$694.9M-9.6%	-$634.2M-15.8%	-$547.5M-13.4%	-$482.8M-10.7%	-$436.2M-10.1%	-$396.3M-27.0%	-$312.1M-27.3%	-$245.3M-29.0%	-$190.2M-34.2%	-$141.7M-16.8%	-$121.3M-44.1%	-$84.2M-48.8%	-$56.6M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$316.7M+98.1%	$356.9M+100.4%	$185.5M+28.7%	$181.4M+42.7%	$159.9M+9.8%	$178.1M+8.2%	$144.2M-13.9%	$127.1M-15.6%
Current Assets	$245.5M+122.4%	$295.5M+132.8%	$123.8M+37.0%	$118.5M+37.4%	$110.4M+6.7%	$126.9M+8.9%	$90.4M-22.8%	$86.3M-11.8%
Cash & Equivalents	$196.6M+164.3%	$255.8M+180.1%	$79.4M+38.6%	$86.2M+46.5%	$74.4M-2.4%	$91.3M+9.0%	$57.3M-29.2%	$58.9M-18.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$8.2M-36.5%	$9.3M-25.6%	$9.6M-33.3%	$11.8M+0.3%	$12.9M+32.7%	$12.5M+18.1%	$14.4M+41.4%	$11.8M+6.9%
Accounts Receivable	$36.2M+131.7%	$25.0M+38.7%	$29.8M+191.1%	$18.0M+68.5%	$15.6M+49.5%	$18.0M+83.9%	$10.2M-32.8%	$10.7M+33.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$110.6M-9.7%	$154.5M+6.1%	$123.4M-15.4%	$116.2M+9.7%	$122.5M-23.6%	$145.6M-13.6%	$145.9M-12.1%	$105.9M-35.3%
Current Liabilities	$62.0M+7.8%	$103.4M+40.3%	$49.7M-30.3%	$54.1M-23.1%	$57.5M-23.9%	$73.7M-16.0%	$71.4M-15.9%	$70.3M-27.8%
Non-Current Liabilities	$48.6M-25.2%	$51.1M-28.9%	$73.6M-1.1%	$62.2M+74.5%	$65.0M-23.3%	$71.9M-11.1%	$74.5M-8.1%	$35.6M-46.4%
Long-Term Debt	$35.0M-30.0%	$37.5M-33.5%	$54.5M-6.0%	$47.8M-9.0%	$50.0M-25.3%	$56.4M-8.2%	$58.0M-4.8%	$52.5M+14.6%
Total Equity	$164.1M+273.7%	$162.2M+629.0%	$49.9M+119.3%	$55.9M+164.0%	$43.9M+145.7%	$22.3M-3.4%	$22.7M+0.9%	$21.2M+26.9%
Retained Earnings	-$624.1M+15.2%	-$623.7M+17.0%	-$734.1M+0.9%	-$730.1M+0.5%	-$736.0M-2.0%	-$751.5M-5.8%	-$740.9M-6.6%	-$734.1M-7.1%

Not reported in any period shown, so not listed: Goodwill.

FBIOP Cash Flow Statement

FBIOP quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$125.9M	-$65.8M+18.0%	-$80.2M+37.5%	-$128.2M+28.5%	-$179.4M-53.9%	-$116.5M-39.3%	-$83.7M+11.9%	-$95.0M+3.9%	-$98.8M-21.6%	-$81.3M-77.5%	-$45.8M-124.8%	-$20.4M-24.8%	-$16.3M+44.9%	-$29.6M-27.8%	-$23.2M-111.8%	-$11.0M
Depreciation & Amortization	N/A	$4.7M+4.4%	$4.5M-25.6%	$6.0M-18.8%	$7.4M+181.1%	$2.6M-29.0%	$3.7M+19.5%	$3.1M+122.3%	$1.4M+19.6%	$1.2M+23.4%	$944K+3530.8%	$26K+13.0%	$23K+35.3%	$17K+466.7%	$3K-86.4%	$22K
Stock-Based Compensation	N/A	$28.7M-11.9%	$32.6M+91.5%	$17.0M-25.9%	$23.0M+18.0%	$19.5M+44.9%	$13.5M+2.0%	$13.2M-12.2%	$15.0M+12.0%	$13.4M+10.5%	$12.1M-15.1%	$14.3M+157.7%	$5.5M-6.0%	$5.9M+62.2%	$3.6M	N/A
Capital Expenditures	N/A	N/A	$0-100.0%	$63K-97.7%	$2.7M-40.5%	$4.6M+137.1%	$1.9M-17.9%	$2.3M-66.9%	$7.1M+992.9%	$648K-89.8%	$6.4M+2150.9%	$283K	$0-100.0%	$40K-25.9%	$54K	$0
Free Cash Flow	N/A	N/A	-$80.2M+37.5%	-$128.3M+29.6%	-$182.1M-50.4%	-$121.1M-41.5%	-$85.6M+12.0%	-$97.3M+8.1%	-$105.9M-29.3%	-$82.0M-57.1%	-$52.2M-152.6%	-$20.7M-26.5%	-$16.3M+45.0%	-$29.7M-27.7%	-$23.2M-112.3%	-$11.0M
Investing Cash Flow	$2.8M	$10.1M+167.5%	-$15.0M-613.3%	-$2.1M+90.8%	-$22.9M-156.6%	$40.5M+665.5%	-$7.2M-135.6%	$20.1M+6.8%	$18.8M+146.8%	-$40.2M-563.8%	-$6.1M-176.9%	$7.9M	N/A	-$188K+32.6%	-$279K+92.7%	-$3.8M
Financing Cash Flow	-$6.5M	$77.4M+9.6%	$70.6M+115.8%	$32.7M-56.5%	$75.3M-49.4%	$149.0M-13.6%	$172.4M+17.5%	$146.7M+189.7%	$50.6M-66.3%	$150.4M+250.5%	$42.9M-29.6%	$60.9M	N/A	$89.2M+120.1%	$40.5M+75.4%	$23.1M
Dividends Paid	N/A	$664K-4.3%	$694K-5.7%	$736K-1.7%	$749K0.0%	$749K+216.0%	$237K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	$70K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$59.3M-115.1%	$203.9M+1142.0%	-$12.5M+2.8%	-$6.1M+69.5%	-$27.6M-26.2%	-$19.6M+22.9%	-$12.9M+63.1%	-$20.1M-19.5%
Depreciation & Amortization	$1.1M-8.2%	$1.2M+2.4%	$1.2M+2.8%	$1.2M+27.4%	$1.2M-4.1%	$1.2M0.0%	$1.1M-5.6%	$914K-24.7%
Stock-Based Compensation	$2.9M-82.9%	$1.8M-72.1%	N/A	$3.2M-51.4%	$16.8M+236.0%	$6.3M+29.5%	N/A	$6.6M+50.2%
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	-$1.4M+139400.0%
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$12.9M+63.1%	-$21.5M-27.9%
Investing Cash Flow	-$79K-101.3%	$0-100.0%	$0+100.0%	$2.9M	$6.1M	$1.2M	-$15.0M-23709.5%	$0-100.0%
Financing Cash Flow	$91K-98.0%	-$27.4M-152.5%	$5.7M-77.9%	$15.1M+456.0%	$4.5M-68.3%	$52.1M+87.2%	$25.8M-40.8%	$2.7M+201.0%
Dividends Paid	N/A	$0-100.0%	$166K0.0%	$166K-5.7%	$166K-5.7%	$166K-5.7%	$166K-7.8%	$176K-4.9%

Not reported in any period shown, so not listed: Share Buybacks.

FBIOP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FBIOP quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	66.9%+3.1pp	63.8%-9.1pp	72.9%+13.5pp	59.4%+6.0pp	53.4%-14.6pp	68.0%-3.3pp	71.3%-6.0pp	77.2%-1.6pp	78.8%-16.4pp	95.2%-4.8pp	100.0%	N/A	N/A	N/A	N/A
Operating Margin	-111.0%	-191.4%	-168.4%	-268.8%	-274.1%	-206.7%	-302.5%	-446.4%	-520.7%	-398.7%	-5855.3%	N/A	N/A	N/A	N/A
Net Margin	58.5%+22.1pp	36.4%-0.3pp	36.7%	-114.3%	-94.1%	-102.0%	-109.1%	-313.0%	-387.8%	-334.3%	-5611.6%	N/A	N/A	N/A	N/A
Return on Equity	74.2%-18.2pp	92.4%-45.1pp	137.5%+345.0pp	-207.5%-148.0pp	-59.5%-13.2pp	-46.4%+106.1pp	-152.4%+4391.1pp	-4543.6%-4416.4pp	-127.2%+15.9pp	-143.1%-57.9pp	-85.2%-56.3pp	-28.9%+16.8pp	-45.7%+79.6pp	-125.3%+64.7pp	-190.1%
Return on Assets	19.9%+5.4pp	14.6%-3.9pp	18.5%+47.9pp	-29.4%-13.1pp	-16.3%-2.4pp	-14.0%+3.7pp	-17.6%+42.0pp	-59.7%-32.5pp	-27.2%+5.1pp	-32.3%+8.6pp	-40.8%-18.0pp	-22.8%+14.1pp	-36.9%+30.4pp	-67.3%+88.2pp	-155.6%
Current Ratio	2.49+1.2x	1.27-0.1x	1.38-0.4x	1.80-1.6x	3.43-1.7x	5.14+1.7x	3.43+1.4x	2.00-0.6x	2.56+0.6x	1.94-7.5x	9.45-7.8x	17.28+8.4x	8.92+1.0x	7.91+1.2x	6.69
Debt-to-Equity	1.09-1.5x	2.55-0.2x	2.70+0.5x	2.20+1.8x	0.40-0.1x	0.52-2.7x	3.23-42.3x	45.58+44.3x	1.28+0.5x	0.79+0.4x	0.42+0.2x	0.200.0x	0.24-0.6x	0.86+0.6x	0.22
Asset Turnover	0.34-0.1x	0.40-0.1x	0.50+0.2x	0.26+0.1x	0.170.0x	0.140.0x	0.160.0x	0.19+0.1x	0.070.0x	0.10+0.1x	0.010.0x	0.000.0x	0.00	N/A	N/A
FCF Margin	N/A	-139.0%	-151.8%	-240.4%	-176.0%	-187.7%	-265.6%	-394.1%	-475.2%	-316.6%	-2394.1%	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	67.2%-2.7pp	61.2%-2.3pp	66.2%-2.9pp	67.4%-2.1pp	69.9%+8.4pp	63.5%+9.6pp	69.0%-19.7pp	69.4%-12.1pp
Operating Margin	-53.5%	-48.3%	-28.7%	-38.6%	-222.2%	-169.8%	-158.3%	-151.0%
Net Margin	-2.5%-96.9pp	688.2%	163.2%	33.2%+121.1pp	94.3%+167.9pp	-80.5%	398.4%	-88.0%-73.4pp
Return on Equity	-0.3%-35.6pp	68.0%+115.6pp	52.6%-212.3pp	10.5%+71.3pp	35.3%+96.5pp	-47.6%+19.4pp	264.9%-100.4pp	-60.8%-30.6pp
Return on Assets	-0.1%-9.8pp	30.9%+36.9pp	14.1%-27.6pp	3.2%+13.3pp	9.7%+17.2pp	-5.9%+3.4pp	41.8%-7.4pp	-10.1%-6.8pp
Current Ratio	3.96+2.0x	2.86+1.1x	2.49+1.2x	2.19+1.0x	1.92+0.6x	1.72+0.4x	1.27-0.1x	1.23+0.2x
Debt-to-Equity	0.21-0.9x	0.23-2.3x	1.09-1.5x	0.86-1.6x	1.14-2.6x	2.53-0.1x	2.55-0.2x	2.48-0.3x
Asset Turnover	0.060.0x	0.040.0x	0.090.0x	0.100.0x	0.100.0x	0.070.0x	0.100.0x	0.12-0.1x
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-85.4%	-146.6%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Fortress Biotech Inc FBIOP	FY2025	$63.3M	$37.0M	58.5%	N/A	28/100
Tempest Therapeutics Inc TPST	FY2025	N/A	-$26.3M	N/A	$18.2M	—
Acrivon Therapeutics, Inc. ACRV	FY2025	N/A	-$77.9M	N/A	$92.1M	—
Radiopharm Theranostics Ltd RADX	FY2025	$3.6M	-$38.3M	N/A	$31.2M	20/100
Outlook Therapeutics Inc OTLK	FY2025	$1.4M	-$62.4M	N/A	$151.2M	37/100
Verrica Pharmaceuticals VRCA	FY2025	$35.6M	-$17.9M	-50.3%	$92.6M	68/100

Where Fortress Biotech Inc Ranks

Frequently Asked Questions

What is Fortress Biotech Inc's annual revenue?

Fortress Biotech Inc (FBIOP) reported $63.3M in total revenue for fiscal year 2025. This represents a 9.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Fortress Biotech Inc's revenue growing?

Fortress Biotech Inc (FBIOP) revenue grew by 9.7% year-over-year, from $57.7M to $63.3M in fiscal year 2025.

Is Fortress Biotech Inc profitable?

Yes, Fortress Biotech Inc (FBIOP) reported a net income of $37.0M in fiscal year 2025, with a net profit margin of 58.5%.

What is Fortress Biotech Inc's EBITDA?

Fortress Biotech Inc (FBIOP) had EBITDA of -$65.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Fortress Biotech Inc have?

As of fiscal year 2025, Fortress Biotech Inc (FBIOP) had $79.4M in cash and equivalents against $54.5M in long-term debt.

What is Fortress Biotech Inc's gross margin?

Fortress Biotech Inc (FBIOP) had a gross margin of 66.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Fortress Biotech Inc's net profit margin?

Fortress Biotech Inc (FBIOP) had a net profit margin of 58.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Fortress Biotech Inc's return on equity (ROE)?

Fortress Biotech Inc (FBIOP) has a return on equity of 74.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Fortress Biotech Inc's operating cash flow?

Fortress Biotech Inc (FBIOP) recorded an outflow of $65.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Fortress Biotech Inc's total assets?

Fortress Biotech Inc (FBIOP) had $185.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Fortress Biotech Inc spend on research and development?

Fortress Biotech Inc (FBIOP) invested $11.9M in research and development during fiscal year 2025.

How many shares does Fortress Biotech Inc have outstanding?

Fortress Biotech Inc (FBIOP) had 31M shares outstanding as of fiscal year 2025.

What is Fortress Biotech Inc's current ratio?

Fortress Biotech Inc (FBIOP) had a current ratio of 2.49 as of fiscal year 2025, which is generally considered healthy.

What is Fortress Biotech Inc's debt-to-equity ratio?

Fortress Biotech Inc (FBIOP) had a debt-to-equity ratio of 1.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Fortress Biotech Inc's return on assets (ROA)?

Fortress Biotech Inc (FBIOP) had a return on assets of 19.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Fortress Biotech Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Fortress Biotech Inc (FBIOP) held $79.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $65.8M over that year. Dividing the one by the other, the reported balance equals about 14 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Fortress Biotech Inc's Piotroski F-Score?

Fortress Biotech Inc (FBIOP) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Fortress Biotech Inc's earnings high quality?

For every $1 of reported earnings, Fortress Biotech Inc (FBIOP) used $1.78 of operating cash (-$65.8M OCF vs $37.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Fortress Biotech Inc cover its interest payments?

Fortress Biotech Inc (FBIOP) reported an operating loss of $70.2M against $10.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Fortress Biotech Inc?

Fortress Biotech Inc (FBIOP) scores 28 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.